The Role of Doxorubicin in the Formation of Cardiotoxicity – Generally Accepted Statement. Part I. Prevalence and Mechanisms of Formation (Review)
Introduction. Long-term use of anthracyclines during cancer chemotherapy has been associated with the development of potentially life-threatening cardiotoxicity. Despite researches ongoing since the middle of the last century, approaches to the choice of therapy remain limited.Text. Doxorubicin curr...
| Published in: | Разработка и регистрация лекарственных средств |
|---|---|
| Main Authors: | D. A. Andreev, E. I. Balakin, A. S. Samoilov, V. I. Pustovoit |
| Format: | Article |
| Language: | Russian |
| Published: |
LLC Center of Pharmaceutical Analytics (LLC «CPHA»)
2024-03-01
|
| Subjects: | |
| Online Access: | https://www.pharmjournal.ru/jour/article/view/1720 |
Similar Items
The role of doxorubicin in the formation of cardiotoxicity is a consensus statement. Part II. Cardiotoxicity of doxorubicin unrelated to myocytes and cardioprotection strategy (review)
by: D. A. Andreev, et al.
Published: (2024-09-01)
by: D. A. Andreev, et al.
Published: (2024-09-01)
Cardiotoxicity of doxorubicin – causes, prevention, prospects
by: Paweł Wesołowski, et al.
Published: (2022-11-01)
by: Paweł Wesołowski, et al.
Published: (2022-11-01)
Protection against Doxorubicin-Induced Cardiotoxicity by Ergothioneine
by: Irwin K. Cheah, et al.
Published: (2023-01-01)
by: Irwin K. Cheah, et al.
Published: (2023-01-01)
Potential Roles of Melatonin in Doxorubicin-Induced Cardiotoxicity: From Cellular Mechanisms to Clinical Application
by: Tanawat Attachaipanich, et al.
Published: (2023-02-01)
by: Tanawat Attachaipanich, et al.
Published: (2023-02-01)
microRNA-377 Signaling Modulates Anticancer Drug-Induced Cardiotoxicity in Mice
by: John Henderson, et al.
Published: (2021-08-01)
by: John Henderson, et al.
Published: (2021-08-01)
The beneficial role of exercise in preventing doxorubicin-induced cardiotoxicity
by: Samantha L. Gaytan, et al.
Published: (2023-03-01)
by: Samantha L. Gaytan, et al.
Published: (2023-03-01)
Anthracycline-Induced Cardiotoxicity
by: Radomír Hrdina, et al.
Published: (2000-01-01)
by: Radomír Hrdina, et al.
Published: (2000-01-01)
Prevention and management of anthracycline induced cardiotoxicity: A review
by: Ian Osoro, et al.
Published: (2022-12-01)
by: Ian Osoro, et al.
Published: (2022-12-01)
Temporal Dynamics of Extracellular Matrix Remodeling in Anthracycline-Induced Cardiotoxicity
by: Fibi Meshrkey, et al.
Published: (2025-09-01)
by: Fibi Meshrkey, et al.
Published: (2025-09-01)
Analysis of Models of Doxorubicin-Induced Cardiomyopathy in Rats and Mice. A Modern View From the Perspective of the Pathophysiologist and the Clinician
by: Ekaterina Yu Podyacheva, et al.
Published: (2021-06-01)
by: Ekaterina Yu Podyacheva, et al.
Published: (2021-06-01)
Cardioprotective potential of botanical agents against anthracycline-induced cardiotoxicity
by: Parisa Firoozbakhsh, et al.
Published: (2024-05-01)
by: Parisa Firoozbakhsh, et al.
Published: (2024-05-01)
Luteolin Attenuates Doxorubicin-Induced Cardiotoxicity Through Promoting Mitochondrial Autophagy
by: Haixia Xu, et al.
Published: (2020-02-01)
by: Haixia Xu, et al.
Published: (2020-02-01)
Clinical and preclinical evidence of sex-related differences in anthracycline-induced cardiotoxicity
by: Becky Meiners, et al.
Published: (2018-08-01)
by: Becky Meiners, et al.
Published: (2018-08-01)
Systemic and cardiac susceptibility of immune compromised mice to doxorubicin
by: Amanda J. Favreau-Lessard, et al.
Published: (2019-04-01)
by: Amanda J. Favreau-Lessard, et al.
Published: (2019-04-01)
Review on the Role of Epigenetic Modifications in Doxorubicin-Induced Cardiotoxicity
by: Himani Kumari, et al.
Published: (2020-05-01)
by: Himani Kumari, et al.
Published: (2020-05-01)
Photobiomodulation Therapy Reduces Oxidative Stress and Inflammation to Alleviate the Cardiotoxic Effects of Doxorubicin in Human Stem Cell-Derived Ventricular Cardiomyocytes
by: Guilherme Rabelo Nasuk, et al.
Published: (2025-07-01)
by: Guilherme Rabelo Nasuk, et al.
Published: (2025-07-01)
Mitophagy in Doxorubicin-Induced Cardiotoxicity: Insights into Molecular Biology and Novel Therapeutic Strategies
by: Heng Zhang, et al.
Published: (2024-12-01)
by: Heng Zhang, et al.
Published: (2024-12-01)
Mechanisms of Anthracycline-Induced Cardiotoxicity: Is Mitochondrial Dysfunction the Answer?
by: Alessandra Murabito, et al.
Published: (2020-03-01)
by: Alessandra Murabito, et al.
Published: (2020-03-01)
Doxorubicin-Induced Cardiotoxicity in Collaborative Cross (CC) Mice Recapitulates Individual Cardiotoxicity in Humans
by: Caroline J. Zeiss, et al.
Published: (2019-08-01)
by: Caroline J. Zeiss, et al.
Published: (2019-08-01)
The risk of peripartum cardiomyopathy among pediatric, adolescent, and young adult cancer patients exposed to doxorubicin: an opinion article
by: Christina Carfagnini, et al.
Published: (2024-11-01)
by: Christina Carfagnini, et al.
Published: (2024-11-01)
Cardiac events among patients with sarcoma treated with doxorubicin by method of infusion: A real‐world database study
by: Lee D. Cranmer, et al.
Published: (2023-01-01)
by: Lee D. Cranmer, et al.
Published: (2023-01-01)
Activation of CISD2 as a protective strategy against doxorubicin-induced cardiotoxicity
by: Yi-Ju Chou, et al.
Published: (2025-10-01)
by: Yi-Ju Chou, et al.
Published: (2025-10-01)
An update of the molecular mechanisms underlying anthracycline induced cardiotoxicity
by: Sicong Xie, et al.
Published: (2024-06-01)
by: Sicong Xie, et al.
Published: (2024-06-01)
Protective Effects of <i>Hippophae rhamnoides</i> L. Phenylpropanoids on Doxorubicin-Induced Cardiotoxicity in Zebrafish
by: Gang Li, et al.
Published: (2022-12-01)
by: Gang Li, et al.
Published: (2022-12-01)
Correction: An update of the molecular mechanisms underlying anthracycline induced cardiotoxicity
by: Sicong Xie, et al.
Published: (2025-09-01)
by: Sicong Xie, et al.
Published: (2025-09-01)
Electrocardiographic characteristics of Nigerian children on anthracycline-based chemotherapy: A preliminary report
by: I D Peter, et al.
Published: (2017-01-01)
by: I D Peter, et al.
Published: (2017-01-01)
Cardiotoxic drugs Herceptin and doxorubicin inhibit cardiac microvascular endothelial cell barrier formation resulting in increased drug permeability
by: Emma L. Wilkinson, et al.
Published: (2016-10-01)
by: Emma L. Wilkinson, et al.
Published: (2016-10-01)
PPARα Ameliorates Doxorubicin-Induced Cardiotoxicity by Reducing Mitochondria-Dependent Apoptosis via Regulating MEOX1
by: Wei Wang, et al.
Published: (2020-10-01)
by: Wei Wang, et al.
Published: (2020-10-01)
Lipidomics application to explain acute cardiotoxicity induced by doxorubicin
by: Lubna Zuhair Abdul Karim, et al.
Published: (2019-12-01)
by: Lubna Zuhair Abdul Karim, et al.
Published: (2019-12-01)
Use of indicators of systolic and diastolic functions of the left ventricle in the diagnosis of early cardiotoxicity during chemotherapy with doxorubicin: An open, prospective, nonrandomized study
by: Irina A. Karputs, et al.
Published: (2024-08-01)
by: Irina A. Karputs, et al.
Published: (2024-08-01)
Dapagliflozin May Protect Against Doxorubicin-Induced Cardiotoxicity
by: Sebahat Ulusan, et al.
Published: (2023-05-01)
by: Sebahat Ulusan, et al.
Published: (2023-05-01)
Recent Advances in the Mechanisms of Cell Death and Dysfunction in Doxorubicin Cardiotoxicity
by: Tian-Hu Wang, et al.
Published: (2023-11-01)
by: Tian-Hu Wang, et al.
Published: (2023-11-01)
Investigation of the efficacy of tyrosol on doxorubicin-induced acute cardiotoxicity in rats
by: Mustafa Cellat, et al.
Published: (2022-09-01)
by: Mustafa Cellat, et al.
Published: (2022-09-01)
The Role of miRNAs in Chemotherapy-Induced Cardiotoxicity
by: Maria Anastasiou, et al.
Published: (2025-09-01)
by: Maria Anastasiou, et al.
Published: (2025-09-01)
Therapeutic Potential of Ginsenosides in Anthracycline-Induced Cardiotoxicity
by: Rongrong Bai, et al.
Published: (2025-06-01)
by: Rongrong Bai, et al.
Published: (2025-06-01)
Pharmacological interventions to prevent cardiotoxicity in patients undergoing anthracycline-based chemotherapy: a network meta-analysis
by: Xiaoyu Liu, et al.
Published: (2025-09-01)
by: Xiaoyu Liu, et al.
Published: (2025-09-01)
Curcumin exerts protective effects against doxorubicin-induced cardiotoxicity
by: O. О. Klymenko, et al.
Published: (2025-02-01)
by: O. О. Klymenko, et al.
Published: (2025-02-01)
Anthracycline-induced cardiotoxicity – primary preventive options. An overview
by: S. Slavcheva
Published: (2024-05-01)
by: S. Slavcheva
Published: (2024-05-01)
Effect of pimobendan on cytokine levels in doxorubicin-induced cardiotoxicity
by: Burak Dik, et al.
by: Burak Dik, et al.
Cardiotoxicity: Importance of biomarkers
by: Kostadinović Jelena, et al.
Published: (2023-01-01)
by: Kostadinović Jelena, et al.
Published: (2023-01-01)
Similar Items
-
The role of doxorubicin in the formation of cardiotoxicity is a consensus statement. Part II. Cardiotoxicity of doxorubicin unrelated to myocytes and cardioprotection strategy (review)
by: D. A. Andreev, et al.
Published: (2024-09-01) -
Cardiotoxicity of doxorubicin – causes, prevention, prospects
by: Paweł Wesołowski, et al.
Published: (2022-11-01) -
Protection against Doxorubicin-Induced Cardiotoxicity by Ergothioneine
by: Irwin K. Cheah, et al.
Published: (2023-01-01) -
Potential Roles of Melatonin in Doxorubicin-Induced Cardiotoxicity: From Cellular Mechanisms to Clinical Application
by: Tanawat Attachaipanich, et al.
Published: (2023-02-01) -
microRNA-377 Signaling Modulates Anticancer Drug-Induced Cardiotoxicity in Mice
by: John Henderson, et al.
Published: (2021-08-01)
